REGN - Out on the Tag: LAG-3 Mishap Likely to Weigh on Investors Waiting for Pipeline Value Inflection Point

Research evidence excerpt

REGN - Out on the Tag: LAG-3 Mishap Likely to Weigh on Investors Waiting for Pipeline Value Inflection Point

Truist Securities

Exhibit 2 – Pipeline

Pipeline

Drug/Target Indication Status

wetAMD Marketed

Diabetic macular edema Marketed

Macular edema following RVO (incl. CRVO and BRVO) Marketed

Eylea (anti-VEGF, Bayer) mCNV Marketed (ex-U.S.)

Diabetic retinopathy Marketed (U.S.)

Neovascular glaucoma Marketed (JPN)

Retinopathy of prematurity (ROP) Marketed

AD in adolescents and adults Marketed

AD in pediatrics Marketed

Asthma in asthmaolescents and asthmaults Marketed

Asthma in pediatrics Marketed

CRSwNP Marketed

Dupixent (IL-4R, Sanofi) pediatric AD (6 month to 5 y.o.) Marketed

EoE (peds, adolescent, adult) Marketed

Prurigo nodularis Markted

COPD sBLA-ready

Bullous pemphigoid Phase III

Ulcerative colitis Phase II

Eosinophilic gastritis Phase II

Kevzara (IL-6R antibody, Sanofi) Rheumatoid arthritis, juvenile idiopathic arthritis Marketed, Phase II

Itepekimab (Il-33, Sanofi) COPD Phase III

1L NSCLC, BCC Marketed

1L NSCLC (chemo combotx) Marketed

Libtayo (anti-PD-1, Sanofi) 2L cervical cancer Marketed (EU)

Adjuvant CSCC Marketed

Neoadjuvant CSCC Marketed

Lynozyfic (linvoseltamab) Relapsed and refractory multiple myeloma Marketed

Olatorepatide (GLP/GIP agonist, HS-20094, Hansoh) Obesity Phase III

Fianlimab (REGN3767, LAG-3 antibody) Met melanoma, NSCLC Phase II/III

Vidutolimod (CMP-001) Cancer Vaccine Phase II

REGN4018 (MUC16xCD3) Platinum-resistant ovarian cancer Phase II

REGN5668 (MUC16xCD28) Ovarian cancer Phase I

REGN5678 (PSMAxCD28) Prostate cancer Phase I

REGN4336 (PSMAxCD3) Prostate cancer Phase I

REGN5093 (METxMET) MET-altered advanced NSCLC Phase I

REGN5093-M114 (METxMET) MET-overexpressing advanced cancer Phase I

REGN6569 (GITR antibody) Solid tumors Phase I